CDSCO Panel Nod To Roche Anti Cancer Drug Atezolizumab For Metastatic Triple Negative Breast Cancer

#CDSCO #Atezolizumab #Breast_Cancer #Roche #Oncology #Hematology

CDSCO Panel Nod To Roche Anti Cancer Drug Atezolizumab For Metastatic Triple Negative Breast Cancer

Based on the justification provided by the pharmaceutical giant Roche, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has approved Roche's anticancer drug Atezolizumab for continuation of indication of metastatic triple negative breast cancer.

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy.

Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter:   / medicaldialogs  
Facebook:   / medicaldialogues  
Instagram:   / medicaldialogues  
LinkedIn:   / medical-dialogues  
Website: https://medicaldialogues.in/